混合：用免疫疗法组合来增强反应。

IF 17.5 1区医学 Q1 ONCOLOGY

Trends in cancer Pub Date : 2025-06-01 Epub Date: 2025-05-06 DOI:10.1016/j.trecan.2025.04.013

Hiroki Komatsuda, Edward S Sim, Ravindra Uppaluri

引用次数: 0

摘要

联合新辅助免疫治疗是否能提高头颈癌患者的应答尚不清楚。最近，Li等人证明，与单药治疗相比，新辅助抗pd -1+CTLA-4或抗pd -1+LAG-3治疗的疗效更好。这些组合策略通过不同的机制与不同的生物标志物起作用，突出了个性化新辅助免疫治疗方法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mixing it up: boosting responses with immunotherapy combinations.

Whether combination neoadjuvant immunotherapy can enhance response in patients with head and neck cancer remains unclear. Recently, Li et al. demonstrated improved responses with neoadjuvant anti-PD-1+CTLA-4 or anti-PD-1+LAG-3 compared with anti-PD-1 monotherapy. These combination strategies act via different mechanisms with distinct biomarkers of response, highlighting the potential for personalized neoadjuvant immunotherapy approaches.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Trends in cancer Medicine-Oncology

CiteScore

28.50

自引率

0.50%

发文量

138

期刊介绍： Trends in Cancer, a part of the Trends review journals, delivers concise and engaging expert commentary on key research topics and cutting-edge advances in cancer discovery and medicine. Trends in Cancer serves as a unique platform for multidisciplinary information, fostering discussion and education for scientists, clinicians, policy makers, and patients & advocates.Covering various aspects, it presents opportunities, challenges, and impacts of basic, translational, and clinical findings, industry R&D, technology, innovation, ethics, and cancer policy and funding in an authoritative yet reader-friendly format.